Search research articles
Contact Us
Filters
Showing results (841-850 of 922) with videos related to
Page
of 93
Sort By:
Current Medical Research and Opinion
|
January 30, 2026
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis
Catherine C Coombs, Jennifer A Woyach, Jennifer R Brown, et al.
Internal Medicine Journal
|
September 24, 2023
Chronic lymphocytic leukaemia Australasian consensus practice statement
Mary A Anderson, Rory Bennett, Xavier Badoux, et al.
Blood Advances
|
August 25, 2021
Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma
Karen Thudium Mueller, Stephan A Grupp, Shannon L Maude, et al.
Blood
|
February 17, 2026
Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma
Mark R Dowling, Edward Robert Scheffer Cliff, Anthony Jeffrey, et al.
Blood
|
September 24, 2024
Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE
Jennifer R Brown, Barbara Eichhorst, Nicole Lamanna, et al.
Blood
|
March 8, 2019
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab
John C Byrd, Peter Hillmen, Susan O'Brien, et al.
Blood
|
October 6, 2018
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Ian W Flinn, Peter Hillmen, Marco Montillo, et al.
Blood
|
June 16, 2022
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
Rachel Thijssen, Luyi Tian, Mary Ann Anderson, et al.
Blood
|
March 10, 2019
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
Andrew D Zelenetz, Gilles Salles, Kylie D Mason, et al.
The New England Journal of Medicine
|
December 4, 2018
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J Schuster, Michael R Bishop, Constantine S Tam, et al.
Page
of 93
Search research articles
Search
Showing results (841-850 of 922) with videos related to
Sort By:
Page
of 93
Current Medical Research and Opinion
|
January 30, 2026
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis
Catherine C Coombs, Jennifer A Woyach, Jennifer R Brown, et al.
Internal Medicine Journal
|
September 24, 2023
Chronic lymphocytic leukaemia Australasian consensus practice statement
Mary A Anderson, Rory Bennett, Xavier Badoux, et al.
Blood Advances
|
August 25, 2021
Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma
Karen Thudium Mueller, Stephan A Grupp, Shannon L Maude, et al.
Blood
|
February 17, 2026
Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma
Mark R Dowling, Edward Robert Scheffer Cliff, Anthony Jeffrey, et al.
Blood
|
September 24, 2024
Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE
Jennifer R Brown, Barbara Eichhorst, Nicole Lamanna, et al.
Blood
|
March 8, 2019
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab
John C Byrd, Peter Hillmen, Susan O'Brien, et al.
Blood
|
October 6, 2018
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Ian W Flinn, Peter Hillmen, Marco Montillo, et al.
Blood
|
June 16, 2022
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
Rachel Thijssen, Luyi Tian, Mary Ann Anderson, et al.
Blood
|
March 10, 2019
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
Andrew D Zelenetz, Gilles Salles, Kylie D Mason, et al.
The New England Journal of Medicine
|
December 4, 2018
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J Schuster, Michael R Bishop, Constantine S Tam, et al.
Page
of 93